Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 99-104

  Wang, Chenchen ^a   Hickey, Anthony J ^a  

^a University of North Carolina   (United States)

Author keywords

Cell viability; Efficacy; Microparticles; Nanoparticles; Phagocytosis; Pulmonary delivery

Indexed keywords

NANOPARTICLE; TIOCARLIDE; DIMETHYL SULFOXIDE; PHENYLTHIOUREA; POWDER; SOLVENT; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; SPRAY DRYING; ANALOGS AND DERIVATIVES; BACTERIAL COUNT; CELL LINE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; GROWTH, DEVELOPMENT AND AGING; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PARTICLE SIZE; PATHOLOGY; PHARMACEUTICS; POWDER; PROCEDURES; TOXICITY;

ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; COLONY COUNT, MICROBIAL; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS; NANOPARTICLES; PARTICLE SIZE; PHENYLTHIOUREA; POWDERS; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77955055150     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.037     Document Type: Article

References (25)

1. Leading Article Isoxyl. Tubercle 1965, 46:298-300.
2. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control Release 2002, 79:29-40.
3. Anisimova Y.V., Gelperina S.E., Peloquin C.A., Heifets L.B. Nanoparticles as antituberculosis drugs carriers: effect on activity against M. tuberculosis in human monocyte-derived macrophages. J. Nanoparticle Res. 2000, 2:165-171.
4. Barrow E.L., Winchester G.A., Staas J.K., Quenelle D.C., Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 1998, 42:2682-2689.
5. Bartmann K. Antituberculosis Drugs 1988, Springer-Verlag, New York.
6. Bryskier A., Grosset J. Antimicrobial Agents: Antibacterials and Antifungals 2005, ASM Press, Washington, DC.
7. Caira M., Crider M., De Villers M., Liebenberg W. New synthesis and physicochemical properties of two crystal forms of the antitubercular agent isoxyl. AAPS Annu. Meet. Exposition 2005.
8. Chen H., Langer R., Edwards D.A. A film tension theory of phagocytosis. J. Colloid Interface Sci. 1997, 190:118-133.
9. Fontan P., Aris V., Ghanny S., Soteropoulos P., Smith I. Global transcriptional profile of Mycobacterium tuberculosis during THP-1 human macrophage infection. Infect. Immun. 2008, 76:717-725.
10. Garcia-Contreras L., Sethuraman V., Kazantseva M., Godfrey V., Hickey A.J. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother. 2006, 58:980-986.
11. Jones B.G., Dickinson P.A., Gumbleton M., Kellaway I.W. Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383. J. Pharm. Pharmacol. 2002, 54:1065-1072.
12. Lambelin G., Parmentier R. Study of the toxicity of isoxyl. Research on the pathological effects of isoxyl in the rat undergoing chronic experimentation. Arzneimittelforschung 1966, 16:881-886.
13. Makino K., Nakajima T., Shikamura M., Ito F., Ando S., Kochi C., Inagawa H., Soma G., Terada H. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. B Biointerfaces 2004, 36:35-42.
14. Malik N.N. Drug discovery: past, present and future. Drug Discov. Today 2008, 13:909-912.
15. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26:2401-2416.
16. Oberdoerster G. Effects and fate of inhaled ultrafine particles. ACS symposium series (nanotechnology and the environment) 2005, 117-136.
17. Phetsuksiri B., Baulard A.R., Cooper A.M., Minnikin D.E., Douglas J.D., Besra G.S., Brennan P.J. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob. Agents Chemother. 1999, 43:1042-1051.
18. Riendeau C.J., Kornfeld H. THP-1 cell apoptosis in response to Mycobacterial infection. Infect. Immun. 2003, 71:254-259.
19. Schroeder E.K., De Souza N., Santos D.S., Blanchard J.S., Basso L.A. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 2002, 3:197-225.
20. Stahle I. Monotherapy with 4-4'diisoamyloxythio-carbanilide (isoxyl). Acta Tuberc. Pneumol. Scand 1964, 44:327-334.
21. Tam J.M., Mcconville J.T., Williams R.O., Johnston K.P. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J. Pharm. Sci. 2008, 97:4915-4933.
22. Tousek J. On the clinical effectiveness of Isoxyl. Antibiot. Chemother. 1970, 16:149-155.
23. Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12001-12005.
24. Wang C., Hickey A.J. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. PharmSciTech. 2010, 11(2):538-549.
25. Yadav A.B., Misra A. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity. Antimicrob. Agents Chemother. 2007, 51:3740-3742.